[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Dapagliflozin.]
[A14AA02, stanozolol, Stanozolol may increase the hypoglycemic activities of Dapagliflozin.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Dapagliflozin.]
[J01GA01, streptomycin, Dapagliflozin may increase the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BX02, sucralfate, Dapagliflozin may increase the excretion rate of Sucralfate which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CG01, sulbactam, Dapagliflozin may increase the excretion rate of Sulbactam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01EC02, sulfadiazine, Dapagliflozin may increase the hypoglycemic activities of Sulfadiazine.]
[J01ED01, sulfadimethoxine, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfadimethoxine.]
[A07AB03, sulfaguanidine, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfaguanidine.]
[J01ED02, sulfalene, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfametopyrazine.]
[J01ED07, sulfamerazine, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfamerazine.]
[J01EB03, sulfamethazine, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfamethazine.]
[S01AB01, sulfamethizole, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfamethizole.]
[J01EC01, sulfamethoxazole, Dapagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.]
[J01ED05, sulfamethoxypyridazine, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfamethoxypyridazine.]
[J01EC03, sulfamoxole, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfamoxole.]
[J01EB04, sulfapyridine, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Dapagliflozin can be decreased when combined with Sulfinpyrazone.]
[J01EB01, sulfisomidine, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sulfaisodimidine.]
[S01AB02, sulfisoxazole, Dapagliflozin may increase the hypoglycemic activities of Sulfisoxazole.]
[A10BB04, glibornuride, Dapagliflozin may increase the hypoglycemic activities of Glibornuride.]
[A10BC01, glymidine, Dapagliflozin may increase the hypoglycemic activities of Glymidine.]
[N06DA01, tacrine, The metabolism of Tacrine can be decreased when combined with Dapagliflozin.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Dapagliflozin.]
[N05CD07, temazepam, Dapagliflozin may increase the excretion rate of Temazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CB02, teniposide, The metabolism of Dapagliflozin can be decreased when combined with Teniposide.]
[R03CC03, terbutaline, Dapagliflozin may increase the excretion rate of Terbutaline which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AE07, dabigatran etexilate, Dapagliflozin may increase the excretion rate of Dabigatran etexilate which could result in a lower serum level and potentially a reduction in efficacy.]
[G03BA03, testosterone, Dapagliflozin may increase the excretion rate of Testosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX06, tetrabenazine, The metabolism of Dapagliflozin can be decreased when combined with Tetrabenazine.]
[S03AA02, tetracycline, Dapagliflozin may increase the excretion rate of Tetracycline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AE05, lurasidone, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Lurasidone.]
[A04AD10, dronabinol, The metabolism of Dapagliflozin can be decreased when combined with Dronabinol.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Dapagliflozin.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Thalidomide is combined with Dapagliflozin.]
[R03DA07, theobromine, The metabolism of Theobromine can be decreased when combined with Dapagliflozin.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Dapagliflozin.]
[P02CA02, thiabendazole, Dapagliflozin may increase the excretion rate of Thiabendazole which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AD03, thiethylperazine, Dapagliflozin may increase the excretion rate of Thiethylperazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Dapagliflozin.]
[N05AC02, thioridazine, The metabolism of Dapagliflozin can be decreased when combined with Thioridazine.]
[N05AF04, thiothixene, The metabolism of Thiothixene can be decreased when combined with Dapagliflozin.]
[C01BB04, aprindine, The metabolism of Dapagliflozin can be decreased when combined with Aprindine.]
[G04BE06, moxisylyte, Dapagliflozin may increase the excretion rate of Moxisylyte which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL03, tiapride, Dapagliflozin may increase the excretion rate of Tiapride which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC05, ticlopidine, Dapagliflozin may increase the excretion rate of Ticlopidine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX01, tilidine, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Tilidine.]
[S01ED01, timolol, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Timolol.]
[P01AB02, tinidazole, Dapagliflozin may increase the excretion rate of Tinidazole which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA12, tobramycin, Dapagliflozin may increase the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BB05, tolazamide, Dapagliflozin may increase the hypoglycemic activities of Tolazamide.]
[M02AX02, tolazoline, The risk or severity of adverse effects can be increased when Tolazoline is combined with Dapagliflozin.]
[V04CA01, tolbutamide, Dapagliflozin may increase the hypoglycemic activities of Tolbutamide.]
[N02AX02, tramadol, Dapagliflozin may increase the excretion rate of Tramadol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF04, tranylcypromine, The metabolism of Dapagliflozin can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The metabolism of Dapagliflozin can be decreased when combined with Trazodone.]
[L01XF01, tretinoin, The metabolism of Dapagliflozin can be decreased when combined with Tretinoin.]
[S01BA05, triamcinolone, The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Dapagliflozin.]
[C03DB02, triamterene, The metabolism of Triamterene can be decreased when combined with Dapagliflozin.]
[N05CD05, triazolam, Dapagliflozin may increase the excretion rate of Triazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Trichlormethiazide.]
[A16AX12, trientine, Dapagliflozin may increase the excretion rate of Triethylenetetramine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AB06, trifluoperazine, The metabolism of Trifluoperazine can be decreased when combined with Dapagliflozin.]
[S01AD02, trifluridine, Dapagliflozin may increase the excretion rate of Trifluridine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BA09, clobetasone, The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Dapagliflozin.]
[S01BA10, alclometasone, The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Dapagliflozin.]
[D07AC02, fluclorolone, The risk or severity of hyperglycemia can be increased when Fluclorolone is combined with Dapagliflozin.]
[R03BA07, mometasone, The risk or severity of hyperglycemia can be increased when Mometasone is combined with Dapagliflozin.]
[A03AA05, trimebutine, Dapagliflozin may increase the excretion rate of Trimebutine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AC02, trimethadione, The risk or severity of hypoglycemia can be increased when Trimethadione is combined with Dapagliflozin.]
[C02BA01, trimethaphan, Dapagliflozin may increase the hypotensive activities of Trimethaphan.]
[J01EA01, trimethoprim, Dapagliflozin may increase the excretion rate of Trimethoprim which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Dapagliflozin.]
[R06AC04, tripelennamine, The metabolism of Dapagliflozin can be decreased when combined with Tripelennamine.]
[J01FA08, troleandomycin, The metabolism of Dapagliflozin can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Dapagliflozin can be decreased when combined with Vilazodone.]
[C09CA09, azilsartan medoxomil, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Azilsartan medoxomil.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Dapagliflozin.]
[L01FX04, ipilimumab, Dapagliflozin may increase the excretion rate of Ipilimumab which could result in a lower serum level and potentially a reduction in efficacy.]
[R02AA14, oxyquinoline, Dapagliflozin may increase the excretion rate of Oxyquinoline which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BX03, abiraterone, The serum concentration of Dapagliflozin can be increased when it is combined with Abiraterone.]
[A10BH05, linagliptin, Dapagliflozin may increase the hypoglycemic activities of Linagliptin.]
[J05AP03, boceprevir, The metabolism of Dapagliflozin can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Dapagliflozin can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Dapagliflozin can be decreased when combined with Rilpivirine.]
[S01AA28, vancomycin, Dapagliflozin may increase the excretion rate of Vancomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX21, ezogabine, Dapagliflozin may increase the excretion rate of Ezogabine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AF01, rivaroxaban, Dapagliflozin may increase the excretion rate of Rivaroxaban which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC24, ticagrelor, The metabolism of Dapagliflozin can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Dapagliflozin can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Dapagliflozin can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Dapagliflozin can be decreased when combined with Vinblastine.]
[C04AX07, vincamine, Dapagliflozin may increase the hypotensive activities of Vincamine.]
[B03BA01, vitamin B12, Dapagliflozin may increase the excretion rate of Cyanocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA03, warfarin, The metabolism of Warfarin can be decreased when combined with Dapagliflozin.]
[C03BA10, xipamide, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Xipamide.]
[J05AF01, zidovudine, The metabolism of Dapagliflozin can be decreased when combined with Zidovudine.]
[N05AF05, zuclopenthixol, The metabolism of Dapagliflozin can be decreased when combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Dapagliflozin can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The serum concentration of Dapagliflozin can be increased when it is combined with Vemurafenib.]
[M05BA05, tiludronic acid, Dapagliflozin may increase the excretion rate of Tiludronic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[B06AC02, icatibant, Dapagliflozin may increase the excretion rate of Icatibant which could result in a lower serum level and potentially a reduction in efficacy.]
[L01ED01, crizotinib, The metabolism of Dapagliflozin can be decreased when combined with Crizotinib.]
[R03DC01, zafirlukast, The metabolism of Dapagliflozin can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, Dapagliflozin may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MA13, trovafloxacin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Trovafloxacin.]
[N05AE04, ziprasidone, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Ziprasidone.]
[G03AC10, drospirenone, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Drospirenone.]
[V03AC02, deferiprone, Dapagliflozin may increase the excretion rate of Deferiprone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA01, aspirin, The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Dapagliflozin.]
[L01EJ01, ruxolitinib, Dapagliflozin may increase the excretion rate of Ruxolitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD07, tolterodine, Dapagliflozin may increase the excretion rate of Tolterodine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DH04, doripenem, Dapagliflozin may increase the excretion rate of Doripenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB03, atenolol, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Atenolol.]
[L03AB11, peginterferon alfa-2a, The metabolism of Dapagliflozin can be decreased when combined with Peginterferon alfa-2a.]
[J02AC03, voriconazole, The metabolism of Dapagliflozin can be decreased when combined with Voriconazole.]
[M01CB03, auranofin, Dapagliflozin may increase the excretion rate of Auranofin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Dapagliflozin.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Dapagliflozin.]
[H02AB11, prednylidene, The risk or severity of hyperglycemia can be increased when Prednylidene is combined with Dapagliflozin.]
[B03XA04, peginesatide, Dapagliflozin may increase the excretion rate of Peginesatide which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC07, azacitidine, Dapagliflozin may increase the excretion rate of Azacitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX01, azathioprine, Dapagliflozin may increase the excretion rate of Azathioprine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC05, gemcitabine, Dapagliflozin may increase the excretion rate of Gemcitabine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DF01, aztreonam, Dapagliflozin may increase the excretion rate of Aztreonam which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Dapagliflozin.]
[M03BX01, baclofen, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Baclofen.]
[A08AA11, lorcaserin, The metabolism of Dapagliflozin can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Dapagliflozin can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Dapagliflozin can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Dapagliflozin can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Dapagliflozin can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Linaclotide.]
[L04AA31, teriflunomide, The serum concentration of Dapagliflozin can be decreased when it is combined with Teriflunomide.]
[H02AA01, aldosterone, The risk or severity of hyperglycemia can be increased when Aldosterone is combined with Dapagliflozin.]
[L01EX05, regorafenib, The metabolism of Dapagliflozin can be decreased when combined with Regorafenib.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Dapagliflozin.]
[D02BA02, octinoxate, Dapagliflozin may increase the excretion rate of Octinoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE04, nelfinavir, The metabolism of Dapagliflozin can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The metabolism of Bendamustine can be decreased when combined with Dapagliflozin.]
[N04BD02, rasagiline, Rasagiline may increase the orthostatic hypotensive activities of Dapagliflozin.]
[C08CA13, lercanidipine, The risk or severity of hypoglycemia can be increased when Lercanidipine is combined with Dapagliflozin.]
[N06DA02, donepezil, The metabolism of Dapagliflozin can be decreased when combined with Donepezil.]
[N03AX22, perampanel, The metabolism of Perampanel can be decreased when combined with Dapagliflozin.]
[N02CC03, zolmitriptan, The metabolism of Zolmitriptan can be decreased when combined with Dapagliflozin.]
[G04BD10, darifenacin, The metabolism of Dapagliflozin can be decreased when combined with Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Dapagliflozin may increase the excretion rate of Fludeoxyglucose (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Dapagliflozin.]
[H01CB05, pasireotide, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Pasireotide.]
[G04BE03, sildenafil, The metabolism of Dapagliflozin can be decreased when combined with Sildenafil.]
[V08CA11, gadofosveset, Dapagliflozin may increase the excretion rate of Gadofosveset trisodium which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Dapagliflozin.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Dapagliflozin.]
[A16AX08, teduglutide, Dapagliflozin may increase the excretion rate of Teduglutide which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AX11, bencyclane, The risk or severity of hypoglycemia can be increased when Bencyclane is combined with Dapagliflozin.]
[A10BH04, alogliptin, Dapagliflozin may increase the hypoglycemic activities of Alogliptin.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Dapagliflozin can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be decreased when combined with Dapagliflozin.]
[G03XC05, ospemifene, The metabolism of Dapagliflozin can be decreased when combined with Ospemifene.]
[A10BK02, canagliflozin, Dapagliflozin may increase the hypoglycemic activities of Canagliflozin.]
[J01MA15, gemifloxacin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Gemifloxacin.]
[M04AB03, benzbromarone, The metabolism of Dapagliflozin can be decreased when combined with Benzbromarone.]
[S01AE07, moxifloxacin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Dapagliflozin can be decreased when combined with Tegaserod.]
[H03AA04, tiratricol, Tiratricol may decrease the hypoglycemic activities of Dapagliflozin.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Dapagliflozin is combined with Insulin detemir.]
[R02AD01, benzocaine, The metabolism of Benzocaine can be decreased when combined with Dapagliflozin.]
[A10BX05, pramlintide, Dapagliflozin may increase the hypoglycemic activities of Pramlintide.]
[L03AA12, ancestim, Dapagliflozin may increase the excretion rate of Ancestim which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH01, celecoxib, The metabolism of Dapagliflozin can be decreased when combined with Celecoxib.]
[L04AA18, everolimus, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Everolimus.]
[N04AC01, benztropine, Dapagliflozin may increase the excretion rate of Benzatropine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EC02, dabrafenib, The serum concentration of Dapagliflozin can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, Dapagliflozin may increase the excretion rate of Benzydamine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EE01, trametinib, Dapagliflozin may increase the excretion rate of Trametinib which could result in a lower serum level and potentially a reduction in efficacy.]
[P03AX06, benzyl alcohol, The metabolism of Benzyl alcohol can be decreased when combined with Dapagliflozin.]
[V09AX05, florbetapir F-18, Dapagliflozin may increase the excretion rate of Florbetapir (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX28, levomilnacipran, The risk or severity of hypoglycemia can be increased when Levomilnacipran is combined with Dapagliflozin.]
[C08EA02, bepridil, The metabolism of Dapagliflozin can be decreased when combined with Bepridil.]
[C02KX05, riociguat, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Riociguat.]
[A10BJ03, lixisenatide, Dapagliflozin may increase the hypoglycemic activities of Lixisenatide.]
[C02KX04, macitentan, Dapagliflozin may increase the excretion rate of Macitentan which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Dapagliflozin.]
[N06AX26, vortioxetine, Dapagliflozin may increase the excretion rate of Vortioxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[G03AC08, etonogestrel, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Etonogestrel.]
[J05AP05, simeprevir, The metabolism of Dapagliflozin can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Dapagliflozin may increase the excretion rate of Sofosbuvir which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA13, fusidic acid, The metabolism of Dapagliflozin can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Pipemidic acid.]
[C01CA27, droxidopa, Dapagliflozin may increase the excretion rate of Droxidopa which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB04, acebutolol, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Acebutolol.]
[N05CH03, tasimelteon, Dapagliflozin may increase the excretion rate of Tasimelteon which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AA07, metreleptin, The metabolism of Dapagliflozin can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Dapagliflozin can be increased when combined with Apremilast.]
[L02BG02, formestane, Dapagliflozin may increase the excretion rate of Formestane which could result in a lower serum level and potentially a reduction in efficacy.]
[S03BA03, betamethasone, The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Dapagliflozin.]
[S01ED02, betaxolol, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Betaxolol.]
[V03AB34, fomepizole, Dapagliflozin may increase the excretion rate of Fomepizole which could result in a lower serum level and potentially a reduction in efficacy.]
[C02CC01, bethanidine, Dapagliflozin may increase the hypotensive activities of Bethanidine.]
[A10BJ04, albiglutide, Dapagliflozin may increase the hypoglycemic activities of Albiglutide.]
[L04AC11, siltuximab, The metabolism of Dapagliflozin can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Ceritinib.]
[B01AA07, acenocoumarol, The metabolism of Acenocoumarol can be decreased when combined with Dapagliflozin.]
[L01XH04, belinostat, The metabolism of Dapagliflozin can be increased when combined with Belinostat.]
[A10BK03, empagliflozin, Empagliflozin may increase the diuretic activities of Dapagliflozin.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Dapagliflozin.]
[V08AA01, diatrizoic acid, Dapagliflozin may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AA04, iothalamic acid, Dapagliflozin may increase the excretion rate of Diatrizoate which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX10, eliglustat, The metabolism of Dapagliflozin can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Dapagliflozin can be decreased when combined with Oritavancin.]
[A06AB04, phenolphthalein, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Phenolphthalein.]
[A10BJ05, dulaglutide, Dapagliflozin may increase the hypoglycemic activities of Dulaglutide.]
[A06AH03, naloxegol, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Naloxegol.]
[N04AA02, biperiden, The metabolism of Dapagliflozin can be decreased when combined with Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Dapagliflozin.]
[A06AG02, bisacodyl, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Bisacodyl.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Dapagliflozin.]
[B01AA01, dicumarol, The metabolism of Dapagliflozin can be decreased when combined with Dicoumarol.]
[B01AF03, edoxaban, Dapagliflozin may increase the excretion rate of Edoxaban which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX11, mirtazapine, The metabolism of Mirtazapine can be decreased when combined with Dapagliflozin.]
[L04AC10, secukinumab, The metabolism of Dapagliflozin can be increased when combined with Secukinumab.]
[L01XH03, panobinostat, The metabolism of Dapagliflozin can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, Dapagliflozin may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DC01, bleomycin, Dapagliflozin may increase the excretion rate of Bleomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AP06, asunaprevir, The metabolism of Dapagliflozin can be decreased when combined with Asunaprevir.]
[A07DA06, eluxadoline, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Eluxadoline.]
[N05AX16, brexpiprazole, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Brexpiprazole.]
[A04AD14, rolapitant, The metabolism of Dapagliflozin can be decreased when combined with Rolapitant.]
[A06AD03, magnesium peroxide, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Magnesium peroxide.]
[A10BF01, acarbose, Dapagliflozin may increase the hypoglycemic activities of Acarbose.]
[M02AA25, aceclofenac, Dapagliflozin may increase the excretion rate of Aceclofenac which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AB11, acemetacin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Acemetacin.]
[S01EC01, acetazolamide, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Acetazolamide.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Dapagliflozin is combined with Insulin degludec.]
[A02BC03, lansoprazole, The metabolism of Dapagliflozin can be decreased when combined with Lansoprazole.]
[V03AB37, idarucizumab, Dapagliflozin may increase the excretion rate of Idarucizumab which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Dapagliflozin.]
[J02AC05, isavuconazole, The metabolism of Dapagliflozin can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The serum concentration of Dapagliflozin can be decreased when it is combined with Osimertinib.]
[L01XG03, ixazomib, Dapagliflozin may increase the excretion rate of Ixazomib which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC27, selexipag, Dapagliflozin may increase the hypotensive activities of Selexipag.]
[A10BB31, acetohexamide, Dapagliflozin may increase the hypoglycemic activities of Acetohexamide.]
[M04AB05, lesinurad, Dapagliflozin may increase the excretion rate of Lesinurad which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA02, aloxiprin, Aloxiprin may increase the hypoglycemic activities of Dapagliflozin.]
[N03AX23, brivaracetam, Dapagliflozin may increase the excretion rate of Brivaracetam which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX52, venetoclax, The metabolism of Dapagliflozin can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, Dapagliflozin may increase the excretion rate of Bromazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC01, bromocriptine, Dapagliflozin may increase the hypoglycemic activities of Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Dapagliflozin may increase the excretion rate of Almasilate which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AC11, amcinonide, The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Dapagliflozin.]
[N06AA19, amineptin, Amineptine may decrease the hypoglycemic activities of Dapagliflozin.]
[C08CA01, amlodipine, The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Dapagliflozin.]
[A05AA04, obeticholic acid, The metabolism of Dapagliflozin can be decreased when combined with Obeticholic acid.]
[C03CA02, bumetanide, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Bumetanide.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Dapagliflozin.]
[C07AA19, bupranolol, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Bupranolol.]
[N07BC01, buprenorphine, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Buprenorphine.]
[L02AE01, buserelin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Buserelin.]
[N05BE01, buspirone, Dapagliflozin may increase the excretion rate of Buspirone which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XX27, arsenic trioxide, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Arsenic trioxide.]
[P01BE02, artemether, The metabolism of Artemether can be decreased when combined with Dapagliflozin.]
[M02AA03, clofezone, Dapagliflozin may increase the excretion rate of Rabeprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AF01, butorphanol, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Butorphanol.]
[J01MA09, sparfloxacin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sparfloxacin.]
[S01GX07, azelastine, The metabolism of Dapagliflozin can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Dapagliflozin can be decreased when combined with Rucaparib.]
[A06AX07, plecanatide, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Plecanatide.]
[L01EF02, ribociclib, The metabolism of Dapagliflozin can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may increase the hypoglycemic activities of Dapagliflozin.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Dapagliflozin.]
[A06AH05, naldemedine, Dapagliflozin may increase the excretion rate of Naldemedine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX16, deutetrabenazine, Dapagliflozin may increase the excretion rate of Deutetrabenazine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BF02, pregabalin, The risk or severity of hypoglycemia can be increased when Pregabalin is combined with Dapagliflozin.]
[N06BC01, caffeine, The metabolism of Dapagliflozin can be decreased when combined with Caffeine.]
[C09AA07, benazepril, The risk or severity of hypoglycemia can be increased when Benazepril is combined with Dapagliflozin.]
[A10BX06, benfluorex, Dapagliflozin may increase the hypoglycemic activities of Benfluorex.]
[P01CA02, benznidazole, Dapagliflozin may increase the excretion rate of Benznidazole which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XX08, linezolid, Linezolid may increase the orthostatic hypotensive activities of Dapagliflozin.]
[J05AF06, abacavir, Dapagliflozin may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE09, tipranavir, The metabolism of Dapagliflozin can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, Dapagliflozin may increase the excretion rate of Valbenazine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AB02, infliximab, The metabolism of Dapagliflozin can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Dapagliflozin can be decreased when combined with Midostaurin.]
[N04BD03, safinamide, Safinamide may increase the orthostatic hypotensive activities of Dapagliflozin.]
[J01MA23, delafloxacin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Delafloxacin.]
[L01BC06, capecitabine, The metabolism of Dapagliflozin can be decreased when combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Dapagliflozin.]
[L01XH01, vorinostat, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Vorinostat.]
[C07AB07, bisoprolol, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Dapagliflozin can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Bopindolol.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Nesiritide is combined with Dapagliflozin.]
[R03BA02, budesonide, The risk or severity of hyperglycemia can be increased when Budesonide is combined with Dapagliflozin.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Dapagliflozin.]
[N06AA15, butriptyline, Butriptyline may decrease the hypoglycemic activities of Dapagliflozin.]
[A10BJ06, semaglutide, Dapagliflozin may increase the hypoglycemic activities of Semaglutide.]
[N01BX04, capsaicin, The metabolism of Dapagliflozin can be increased when combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Ertugliflozin.]
[R06AX18, acrivastine, Dapagliflozin may increase the excretion rate of Acrivastine which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA01, captopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Captopril.]
[L02BB05, apalutamide, The metabolism of Dapagliflozin can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Dapagliflozin can be increased when combined with Carbamazepine.]
[A06AC08, calcium polycarbophil, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Calcium polycarbophil.]
[L03AB06, interferon alfa-n1, The metabolism of Dapagliflozin can be decreased when combined with Interferon alfa-n1.]
[C07AG02, carvedilol, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of hypotension can be increased when Fostamatinib is combined with Dapagliflozin.]
[N03AX24, cannabidiol, The metabolism of Dapagliflozin can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The metabolism of Dapagliflozin can be increased when combined with Avatrombopag.]
[L04AA37, baricitinib, Dapagliflozin may increase the excretion rate of Baricitinib which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Dapagliflozin.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Dapagliflozin.]
[J01DD14, ceftibuten, Dapagliflozin may increase the excretion rate of Ceftibuten which could result in a lower serum level and potentially a reduction in efficacy.]
[J01GB14, plazomicin, Dapagliflozin may increase the excretion rate of Plazomicin which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB08, celiprolol, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Dapagliflozin.]
[L01XX62, ivosidenib, The metabolism of Dapagliflozin can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Dapagliflozin.]
[A16AX14, migalastat, Dapagliflozin may increase the excretion rate of Migalastat which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX17, stiripentol, The metabolism of Dapagliflozin can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Dapagliflozin.]
[S01GX12, cetirizine, Dapagliflozin may increase the excretion rate of Cetirizine which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BB06, carbutamide, Dapagliflozin may increase the hypoglycemic activities of Carbutamide.]
[D08AE05, chloroxylenol, Dapagliflozin may increase the excretion rate of Chloroxylenol which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC05, lornoxicam, The metabolism of Lornoxicam can be decreased when combined with Dapagliflozin.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be decreased when combined with Dapagliflozin.]
[R03BB08, revefenacin, The metabolism of Revefenacin can be decreased when combined with Dapagliflozin.]
[L04AA39, emapalumab, The metabolism of Dapagliflozin can be increased when combined with Emapalumab.]
[L01AD01, carmustine, Dapagliflozin may increase the excretion rate of Carmustine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX05, prucalopride, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Prucalopride.]
[C01BG07, cifenline, The risk or severity of hypoglycemia can be increased when Cibenzoline is combined with Dapagliflozin.]
[C09AA08, cilazapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Cilazapril.]
[B01AC23, cilostazol, Dapagliflozin may increase the excretion rate of Cilostazol which could result in a lower serum level and potentially a reduction in efficacy.]
[P02BX04, triclabendazole, The metabolism of Dapagliflozin can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The metabolism of Esketamine can be decreased when combined with Dapagliflozin.]
[L04AA42, siponimod, The metabolism of Siponimod can be decreased when combined with Dapagliflozin.]
[J01FA09, clarithromycin, The metabolism of Dapagliflozin can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, Dapagliflozin may increase the excretion rate of Solriamfetol which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Dapagliflozin.]
[N05BA09, clobazam, The metabolism of Dapagliflozin can be decreased when combined with Clobazam.]
[D07AB21, clocortolone, The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Dapagliflozin.]
[H02AB14, cloprednol, The risk or severity of hyperglycemia can be increased when Cloprednol is combined with Dapagliflozin.]
[A06AB05, castor oil, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Castor oil.]
[C01EB09, ubidecarenone, The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Dapagliflozin.]
[C09CA06, candesartan, The metabolism of Dapagliflozin can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Dapagliflozin can be increased when combined with Etanercept.]
[H02AB17, cortivazol, The risk or severity of hyperglycemia can be increased when Cortivazol is combined with Dapagliflozin.]
[L01EM03, alpelisib, The serum concentration of Dapagliflozin can be decreased when it is combined with Alpelisib.]
[J01DC04, cefaclor, Dapagliflozin may increase the excretion rate of Cefaclor which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB05, cefadroxil, Dapagliflozin may increase the excretion rate of Cefadroxil which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DC05, cefotetan, Dapagliflozin may increase the excretion rate of Cefotetan which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD02, ceftazidime, Dapagliflozin may increase the excretion rate of Ceftazidime which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BX03, cicletanine, Dapagliflozin may increase the hypotensive activities of Cicletanine.]
[J01DD04, ceftriaxone, Dapagliflozin may increase the excretion rate of Ceftriaxone which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BX08, cyclobenzaprine, The metabolism of Cyclobenzaprine can be decreased when combined with Dapagliflozin.]
[L01EJ02, fedratinib, The metabolism of Dapagliflozin can be decreased when combined with Fedratinib.]
[N07XX11, pitolisant, The serum concentration of Dapagliflozin can be decreased when it is combined with Pitolisant.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Dapagliflozin.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Cyclothiazide.]
[G04BE04, yohimbine, The metabolism of Dapagliflozin can be decreased when combined with Yohimbine.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Dapagliflozin is combined with Insulin pork.]
[A06AB03, danthron, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Dantron.]
[J01XX09, daptomycin, Dapagliflozin may increase the excretion rate of Daptomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB01, cephalexin, Dapagliflozin may increase the excretion rate of Cephalexin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DB09, cephradine, Dapagliflozin may increase the excretion rate of Cefradine which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AB13, deflazacort, The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Dapagliflozin.]
[G03AC09, desogestrel, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Desogestrel.]
[B06AX03, voxelotor, The metabolism of Voxelotor can be decreased when combined with Dapagliflozin.]
[N03AX25, cenobamate, The serum concentration of Dapagliflozin can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Dapagliflozin can be increased when it is combined with Givosiran.]
[M09AX08, golodirsen, Dapagliflozin may increase the excretion rate of Golodirsen which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB02, dexchlorpheniramine, The metabolism of Dapagliflozin can be decreased when combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Dapagliflozin may increase the excretion rate of Dexpanthenol which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX03, dezocine, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Dezocine.]
[L01EX18, avapritinib, The metabolism of Dapagliflozin can be decreased when combined with Avapritinib.]
[L04AA53, teprotumumab, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Teprotumumab.]
[M01AX21, diacetylrhein, The metabolism of Dapagliflozin can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Dapagliflozin can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Dapagliflozin can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The metabolism of Frovatriptan can be decreased when combined with Dapagliflozin.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Dapagliflozin.]
[R02AA03, dichlorobenzyl alcohol, Dapagliflozin may increase the excretion rate of Dichlorobenzyl alcohol which could result in a lower serum level and potentially a reduction in efficacy.]
[G03DB08, dienogest, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Dienogest.]
[D07AC19, difluprednate, The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Dapagliflozin.]
[N02AA08, dihydrocodeine, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Dihydrocodeine.]
[N02CC06, eletriptan, The metabolism of Dapagliflozin can be increased when combined with Eletriptan.]
[M01AH02, rofecoxib, The metabolism of Dapagliflozin can be decreased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Dapagliflozin can be decreased when combined with Bexarotene.]
[C08CA16, clevidipine, Dapagliflozin may increase the excretion rate of Clevidipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BD07, dronedarone, The metabolism of Dapagliflozin can be decreased when combined with Dronedarone.]
[C02AA06, methoserpidine, Dapagliflozin may increase the hypotensive activities of Methoserpidine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Dapagliflozin.]
[L01EX17, capmatinib, The metabolism of Dapagliflozin can be decreased when combined with Capmatinib.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Opicapone.]
[D07XB03, fluprednidene, The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Dapagliflozin.]
[G04BD09, trospium, The metabolism of Dapagliflozin can be decreased when combined with Trospium.]
[V08CA05, mangafodipir, Dapagliflozin may increase the excretion rate of Mangafodipir which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BA14, loteprednol, The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Dapagliflozin.]
[M02AA27, dexketoprofen, Dapagliflozin may increase the excretion rate of Dexketoprofen which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CM02, chlormethiazole, The metabolism of Clomethiazole can be decreased when combined with Dapagliflozin.]
[C08CA17, levamlodipine, The risk or severity of hypoglycemia can be increased when Levamlodipine is combined with Dapagliflozin.]
[P01BB01, proguanil, The metabolism of Dapagliflozin can be decreased when combined with Proguanil.]
[L04AC19, satralizumab, The serum concentration of Dapagliflozin can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Dapagliflozin can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The metabolism of Dapagliflozin can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Chlorothiazide.]
[R06AB04, chlorpheniramine, The metabolism of Dapagliflozin can be decreased when combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Dapagliflozin can be decreased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, Dapagliflozin may increase the hypoglycemic activities of Chlorpropamide.]
[C03BA04, chlorthalidone, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Chlorthalidone.]
[M03BB03, chlorzoxazone, Dapagliflozin may increase the excretion rate of Chlorzoxazone which could result in a lower serum level and potentially a reduction in efficacy.]
[A11CC05, cholecalciferol, The metabolism of Dapagliflozin can be decreased when combined with Cholecalciferol.]
[N02BA03, choline salicylate, Choline salicylate may increase the hypoglycemic activities of Dapagliflozin.]
[N06BX18, vinpocetine, The risk or severity of hypoglycemia can be increased when Vinpocetine is combined with Dapagliflozin.]
[M01AB08, etodolac, Dapagliflozin may increase the excretion rate of Etodolac which could result in a lower serum level and potentially a reduction in efficacy.]
[B06AC06, berotralstat, The metabolism of Dapagliflozin can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Dapagliflozin can be decreased when combined with Lonafarnib.]
[M01AX25, chondroitin sulfates, Dapagliflozin may increase the excretion rate of Chondroitin sulfate which could result in a lower serum level and potentially a reduction in efficacy.]
[P03AX07, abametapir, The serum concentration of Dapagliflozin can be increased when it is combined with Abametapir.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Vericiguat.]
[L01EX21, tepotinib, The metabolism of Dapagliflozin can be decreased when combined with Tepotinib.]
[V03AF12, trilaciclib, The metabolism of Dapagliflozin can be increased when combined with Trilaciclib.]
[N03AX10, felbamate, The metabolism of Dapagliflozin can be decreased when combined with Felbamate.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Dapagliflozin.]
[C01CA19, fenoldopam, Dapagliflozin may increase the excretion rate of Fenoldopam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD15, cefdinir, Dapagliflozin may increase the excretion rate of Cefdinir which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MB07, flumequine, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Flumequine.]
[R03BA03, flunisolide, The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Dapagliflozin.]
[S02BA08, fluocinolone acetonide, The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Dapagliflozin.]
[N02BG07, flupirtine, Dapagliflozin may increase the excretion rate of Flupirtine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC15, formoterol, The metabolism of Dapagliflozin can be decreased when combined with Formoterol.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Dapagliflozin is combined with Insulin human.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Dapagliflozin can be increased when it is combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Dapagliflozin may increase the hypotensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The metabolism of Dapagliflozin can be decreased when combined with Cimetidine.]
[V08CA04, gadoteridol, Dapagliflozin may increase the excretion rate of Gadoteridol which could result in a lower serum level and potentially a reduction in efficacy.]
[N07CA02, cinnarizine, The metabolism of Cinnarizine can be decreased when combined with Dapagliflozin.]
[J01MB06, cinoxacin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Dapagliflozin can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Dapagliflozin can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, Dapagliflozin may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB04, citalopram, The risk or severity of hypoglycemia can be increased when Citalopram is combined with Dapagliflozin.]
[H01AC07, somapacitan, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Somapacitan.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Dapagliflozin.]
[H01AC09, lonapegsomatropin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Lonapegsomatropin.]
[V09AX06, florbetaben f-18, Dapagliflozin may increase the excretion rate of Florbetaben (18F) which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AA04, clemastine, The metabolism of Dapagliflozin can be decreased when combined with Clemastine.]
[M01AG01, mefenamic acid, The metabolism of Mefenamic acid can be decreased when combined with Dapagliflozin.]
[A10BB12, glimepiride, Dapagliflozin may increase the hypoglycemic activities of Glimepiride.]
[A10BB08, gliquidone, Dapagliflozin may increase the hypoglycemic activities of Gliquidone.]
[N06AX25, St. John's wort extract, The metabolism of Dapagliflozin can be increased when combined with St. John's Wort.]
[L01EA06, asciminib, The metabolism of Dapagliflozin can be decreased when combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The metabolism of Dapagliflozin can be decreased when combined with Ropeginterferon alfa-2b.]
[D07AD01, clobetasol, The risk or severity of hyperglycemia can be increased when Clobetasol is combined with Dapagliflozin.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Dapagliflozin.]
[C10AB01, clofibrate, The metabolism of Dapagliflozin can be decreased when combined with Clofibrate.]
[B06AX04, mitapivat, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Mitapivat.]
[N01BB10, levobupivacaine, Dapagliflozin may increase the excretion rate of Levobupivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EJ03, pacritinib, The metabolism of Dapagliflozin can be decreased when combined with Pacritinib.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Dapagliflozin.]
[N03AE01, clonazepam, Dapagliflozin may increase the excretion rate of Clonazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Dapagliflozin.]
[C01EB24, mavacamten, The serum concentration of Dapagliflozin can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Dapagliflozin may increase the excretion rate of Oseltamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BX16, tirzepatide, Dapagliflozin may increase the hypoglycemic activities of Tirzepatide.]
[C03BA03, clopamide, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Clopamide.]
[A04AA01, ondansetron, The metabolism of Ondansetron can be decreased when combined with Dapagliflozin.]
[N05AH02, clozapine, The metabolism of Dapagliflozin can be decreased when combined with Clozapine.]
[A10BX01, guar gum, Dapagliflozin may increase the hypoglycemic activities of Guar gum.]
[A10BK06, sotagliflozin, Dapagliflozin may increase the hypoglycemic activities of Sotagliflozin.]
[D07AC12, halometasone, The risk or severity of hyperglycemia can be increased when Halometasone is combined with Dapagliflozin.]
[H01AC08, somatrogon, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Somatrogon.]
[S02DA02, cocaine, The metabolism of Dapagliflozin can be decreased when combined with Cocaine.]
[C02KB01, metyrosine, Dapagliflozin may increase the hypotensive activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Dapagliflozin can be increased when combined with Bimekizumab.]
[R05DA04, codeine, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Codeine.]
[M04AC01, colchicine, Dapagliflozin may increase the excretion rate of Colchicine which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AA13, leflunomide, The serum concentration of Dapagliflozin can be decreased when it is combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Dapagliflozin.]
[A04AA03, tropisetron, Dapagliflozin may increase the excretion rate of Tropisetron which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BX03, nateglinide, Dapagliflozin may increase the hypoglycemic activities of Nateglinide.]
[H01AC03, mecasermin, Dapagliflozin may increase the hypoglycemic activities of Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Dapagliflozin is combined with Insulin glargine.]
[J01FA15, telithromycin, The metabolism of Dapagliflozin can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Dapagliflozin.]
[J05AB14, valganciclovir, Dapagliflozin may increase the excretion rate of Valganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C05BB03, invert sugar, Dapagliflozin may increase the excretion rate of Invert sugar which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB09, iodixanol, Dapagliflozin may increase the excretion rate of Iodixanol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB05, iopromide, Dapagliflozin may increase the excretion rate of Iopromide which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB07, ioversol, Dapagliflozin may increase the excretion rate of Ioversol which could result in a lower serum level and potentially a reduction in efficacy.]
[V08AB12, ioxilan, Dapagliflozin may increase the excretion rate of Ioxilan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH03, valdecoxib, The metabolism of Dapagliflozin can be decreased when combined with Valdecoxib.]
[H01AX01, pegvisomant, The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Dapagliflozin.]
[N02CC05, almotriptan, Dapagliflozin may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AH04, parecoxib, The metabolism of Parecoxib can be decreased when combined with Dapagliflozin.]
[J02AC02, itraconazole, The metabolism of Dapagliflozin can be decreased when combined with Itraconazole.]
[S01AD03, acyclovir, Dapagliflozin may increase the excretion rate of Acyclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA10, ketazolam, Dapagliflozin may increase the excretion rate of Ketazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA01, imatinib, The serum concentration of Dapagliflozin can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Dapagliflozin can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, Dapagliflozin may increase the hypotensive activities of Lacidipine.]
[A06AD12, lactitol, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Lactitol.]
[N03AX09, lamotrigine, Dapagliflozin may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BA03, cortisone, The risk or severity of hyperglycemia can be increased when Cortisone is combined with Dapagliflozin.]
[N07BC04, lofexidine, Dapagliflozin may increase the excretion rate of Lofexidine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AE04, lomefloxacin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Lomefloxacin.]
[C09AA03, lisinopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Lisinopril.]
[A06AD01, magnesium carbonate, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Magnesium carbonate.]
[C08CA11, manidipine, The metabolism of Dapagliflozin can be decreased when combined with Manidipine.]
[S01BA08, medrysone, The risk or severity of hyperglycemia can be increased when Medrysone is combined with Dapagliflozin.]
[C07AA14, mepindolol, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Mepindolol.]
[H02AB15, meprednisone, The risk or severity of hyperglycemia can be increased when Meprednisone is combined with Dapagliflozin.]
[R06AD07, mequitazine, The metabolism of Dapagliflozin can be decreased when combined with Mequitazine.]
[J01DH02, meropenem, Dapagliflozin may increase the excretion rate of Meropenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AX01, cyclandelate, The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Dapagliflozin.]
[R06AE03, cyclizine, The metabolism of Dapagliflozin can be decreased when combined with Cyclizine.]
[C03DA04, eplerenone, The risk or severity of adverse effects can be increased when Eplerenone is combined with Dapagliflozin.]
[N05AD03, metylperon, Dapagliflozin may increase the excretion rate of Melperone which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Cyclopenthiazide.]
[A10BF02, miglitol, Dapagliflozin may increase the hypoglycemic activities of Miglitol.]
[J05AF07, tenofovir disoproxil, Dapagliflozin may increase the excretion rate of Tenofovir disoproxil which could result in a lower serum level and potentially a reduction in efficacy.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Dapagliflozin.]
[N06AX07, minaprine, Minaprine may increase the orthostatic hypotensive activities of Dapagliflozin.]
[S01XA18, cyclosporine, The metabolism of Dapagliflozin can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the orthostatic hypotensive activities of Dapagliflozin.]
[N06BA07, modafinil, The metabolism of Dapagliflozin can be decreased when combined with Modafinil.]
[C09AA13, moexipril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Moexipril.]
[C10AA07, rosuvastatin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Rosuvastatin.]
[C03XA02, conivaptan, The metabolism of Dapagliflozin can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Moxonidine.]
[J05AF10, entecavir, The metabolism of Entecavir can be decreased when combined with Dapagliflozin.]
[G04BE09, vardenafil, The risk or severity of hypotension can be increased when Vardenafil is combined with Dapagliflozin.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Dapagliflozin.]
[L01AX04, dacarbazine, The metabolism of Dacarbazine can be decreased when combined with Dapagliflozin.]
[G03XA01, danazol, The metabolism of Dapagliflozin can be decreased when combined with Danazol.]
[J04BA02, dapsone, The metabolism of Dapagliflozin can be decreased when combined with Dapsone.]
[C02CC04, debrisoquin, The metabolism of Dapagliflozin can be decreased when combined with Debrisoquine.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Nabilone is combined with Dapagliflozin.]
[M01AX01, nabumetone, The metabolism of Nabumetone can be decreased when combined with Dapagliflozin.]
[N07BB05, nalmefene, Dapagliflozin may increase the excretion rate of Nalmefene which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA15, potassium lactate, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Potassium lactate.]
[C07AB12, nebivolol, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Nebivolol.]
[S01GX04, nedocromil, Dapagliflozin may increase the excretion rate of Nedocromil which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX06, nefazodone, The metabolism of Dapagliflozin can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Dapagliflozin.]
[L02BB02, nilutamide, Dapagliflozin may increase the excretion rate of Nilutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Dapagliflozin.]
[R05DA06, normethadone, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Normethadone.]
[B01AX05, fondaparinux, Dapagliflozin may increase the excretion rate of Fondaparinux which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB10, escitalopram, The serum concentration of Dapagliflozin can be increased when it is combined with Escitalopram.]
[G04BD08, solifenacin, The metabolism of Dapagliflozin can be decreased when combined with Solifenacin.]
[A07EC03, olsalazine, Olsalazine may increase the hypoglycemic activities of Dapagliflozin.]
[N06AA01, desipramine, The metabolism of Dapagliflozin can be decreased when combined with Desipramine.]
[H01BA02, desmopressin, Dapagliflozin may increase the excretion rate of Desmopressin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BA11, desonide, The risk or severity of hyperglycemia can be increased when Desonide is combined with Dapagliflozin.]
[D07XC02, desoximetasone, The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Dapagliflozin.]
[V04CH02, indigo carmine, Dapagliflozin may increase the excretion rate of Indigotindisulfonic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AA03, desoxycorticosterone, The risk or severity of hyperglycemia can be increased when Desoxycortone is combined with Dapagliflozin.]
[J01DH03, ertapenem, Dapagliflozin may increase the excretion rate of Ertapenem which could result in a lower serum level and potentially a reduction in efficacy.]
[C09XA02, aliskiren, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Aliskiren.]
[M01AE12, oxaprozin, Dapagliflozin may increase the excretion rate of Oxaprozin which could result in a lower serum level and potentially a reduction in efficacy.]
[S03BA01, dexamethasone, The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Dapagliflozin.]
[G04BD04, oxybutynin, The metabolism of Dapagliflozin can be decreased when combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Dapagliflozin.]
[L04AB04, adalimumab, The metabolism of Dapagliflozin can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Dapagliflozin can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, Dapagliflozin may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[R05DA09, dextromethorphan, The metabolism of Dapagliflozin can be decreased when combined with Dextromethorphan.]
[N03AC01, paramethadione, The metabolism of Dapagliflozin can be decreased when combined with Paramethadione.]
[N02AC01, dextromoramide, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Dextromoramide.]
[N06AB05, paroxetine, The metabolism of Dapagliflozin can be decreased when combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be decreased when combined with Dapagliflozin.]
[N07BC06, heroin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Diamorphine.]
[C01DA05, pentaerythritol tetranitrate, Dapagliflozin may increase the excretion rate of Pentaerythritol tetranitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Dapagliflozin.]
[P03AC04, permethrin, Dapagliflozin may increase the excretion rate of Permethrin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA01, diazepam, Dapagliflozin may increase the excretion rate of Diazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AH01, diazoxide, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Diazoxide.]
[N06AA08, dibenzepin, Dibenzepin may decrease the hypoglycemic activities of Dapagliflozin.]
[R05DA08, pholcodine, Dapagliflozin may increase the excretion rate of Pholcodine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EC02, dichlorphenamide, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Diclofenamide.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be decreased when combined with Dapagliflozin.]
[A03AA07, dicyclomine, Dapagliflozin may increase the excretion rate of Dicyclomine which could result in a lower serum level and potentially a reduction in efficacy.]
[A07AB02, phthalylsulfathiazole, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Phthalylsulfathiazole.]
[J05AF02, didanosine, Dapagliflozin may increase the excretion rate of Didanosine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DG01, pinacidil, Dapagliflozin may increase the hypotensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Dapagliflozin.]
[A10BG03, pioglitazone, Dapagliflozin may increase the hypoglycemic activities of Pioglitazone.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Pipamperone.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Dapagliflozin.]
[C03CA03, piretanide, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Piretanide.]
[L02AA01, diethylstilbestrol, The metabolism of Dapagliflozin can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Dapagliflozin can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Dapagliflozin.]
[N02BA11, diflunisal, Diflunisal may increase the hypoglycemic activities of Dapagliflozin.]
[C01AA05, digoxin, Dapagliflozin may increase the excretion rate of Digoxin which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DB01, dihydralazine, The metabolism of Dihydralazine can be decreased when combined with Dapagliflozin.]
[N02AA03, hydromorphone, Dapagliflozin may increase the excretion rate of Hydromorphone which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX04, lenalidomide, Dapagliflozin may increase the excretion rate of Lenalidomide which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE08, atazanavir, The metabolism of Dapagliflozin can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Dapagliflozin can be decreased when combined with Treprostinil.]
[H03BC01, potassium perchlorate, Dapagliflozin may increase the excretion rate of Potassium perchlorate which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB04, pralidoxime, Dapagliflozin may increase the excretion rate of Pralidoxime which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AC18, prednicarbate, The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Dapagliflozin.]
[C08DB01, diltiazem, The metabolism of Dapagliflozin can be decreased when combined with Diltiazem.]
[V03AB09, dimercaprol, Dapagliflozin may increase the excretion rate of Dimercaprol which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AX03, dimethyl sulfoxide, Dapagliflozin may increase the excretion rate of Dimethyl sulfoxide which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Dapagliflozin.]
[C05CA03, diosmin, The metabolism of Dapagliflozin can be decreased when combined with Diosmin.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Dapagliflozin.]
[R06AA02, diphenhydramine, The metabolism of Dapagliflozin can be decreased when combined with Diphenhydramine.]
[A07DA01, diphenoxylate, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Diphenoxylate.]
[N05CD10, quazepam, The metabolism of Dapagliflozin can be decreased when combined with Quazepam.]
[C09AA06, quinapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Quinapril.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Dipyridamole is combined with Dapagliflozin.]
[N06AA23, quinupramine, Quinupramine may decrease the hypoglycemic activities of Dapagliflozin.]
[A03FA02, cisapride, The metabolism of Dapagliflozin can be decreased when combined with Cisapride.]
[C09AA05, ramipril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Ramipril.]
[S01XA23, sirolimus, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Sirolimus.]
[N05AL04, remoxipride, The metabolism of Dapagliflozin can be decreased when combined with Remoxipride.]
[S01AX06, resorcinol, Dapagliflozin may increase the excretion rate of Resorcinol which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BA03, disopyramide, Dapagliflozin may increase the hypoglycemic activities of Disopyramide.]
[S02AA12, rifamycin SV, The metabolism of Dapagliflozin can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Dapagliflozin can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The metabolism of Riluzole can be decreased when combined with Dapagliflozin.]
[N05AX08, risperidone, Dapagliflozin may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, Dapagliflozin may increase the excretion rate of Levocetirizine which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB09, ropivacaine, Dapagliflozin may increase the excretion rate of Ropivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MB01, rosoxacin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Rosoxacin.]
[L01EX01, sunitinib, Dapagliflozin may increase the hypoglycemic activities of Sunitinib.]
[A04AD12, aprepitant, The metabolism of Dapagliflozin can be decreased when combined with Aprepitant.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Dapagliflozin.]
[J05AE07, fosamprenavir, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Fosamprenavir.]
[G04BE08, tadalafil, Dapagliflozin may increase the excretion rate of Tadalafil which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC05, ketorolac, The metabolism of Dapagliflozin can be decreased when combined with Ketorolac.]
[C02KX02, ambrisentan, Dapagliflozin may increase the hypotensive activities of Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Dapagliflozin can be increased when it is combined with Ranolazine.]
[H05BA01, salmon calcitonin, Dapagliflozin may increase the excretion rate of Salmon calcitonin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA07, dobutamine, Dapagliflozin may increase the excretion rate of Dobutamine which could result in a lower serum level and potentially a reduction in efficacy.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Dapagliflozin.]
[C01CA04, dopamine, Dapagliflozin may increase the excretion rate of Dopamine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA16, dothiepin, The metabolism of Dapagliflozin can be decreased when combined with Dosulepin.]
[N06AA12, doxepin, Doxepin may decrease the hypoglycemic activities of Dapagliflozin.]
[A06AB06, sennosides, USP, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Sennosides.]
[L01DB01, doxorubicin, The metabolism of Dapagliflozin can be decreased when combined with Doxorubicin.]
[J01AA02, doxycycline, Dapagliflozin may increase the excretion rate of Doxycycline which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AB06, sertraline, The risk or severity of hypoglycemia can be increased when Sertraline is combined with Dapagliflozin.]
[N01AB08, sevoflurane, The metabolism of Dapagliflozin can be decreased when combined with Sevoflurane.]
[A08AA10, sibutramine, Dapagliflozin may increase the excretion rate of Sibutramine which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA01, simvastatin, The metabolism of Dapagliflozin can be decreased when combined with Simvastatin.]
[V03AG05, sodium phosphate, Dapagliflozin may increase the nephrotoxic activities of Sodium phosphate, monobasic.]
[A12CA02, sodium sulfate, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Sodium sulfate.]
[C09AA11, spirapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Spirapril.]
[R03DA01, dyphylline, Dapagliflozin may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[A07AB04, succinylsulfathiazole, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Succinylsulfathiazole.]
[N02CC01, sumatriptan, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sumatriptan.]
[V04CX07, edrophonium, Dapagliflozin may increase the excretion rate of Edrophonium which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB13, talinolol, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Talinolol.]
[H01AA01, corticotropin, The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Dapagliflozin.]
[J01MA05, temafloxacin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Temafloxacin.]
[L01AX03, temozolomide, Dapagliflozin may increase the excretion rate of Temozolomide which could result in a lower serum level and potentially a reduction in efficacy.]
[M01AC02, tenoxicam, The metabolism of Dapagliflozin can be decreased when combined with Tenoxicam.]
[G04CA03, terazosin, The risk or severity of adverse effects can be increased when Terazosin is combined with Dapagliflozin.]
[D01BA02, terbinafine, The metabolism of Dapagliflozin can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of hypoglycemia can be increased when Terodiline is combined with Dapagliflozin.]
[C07AA16, tertatolol, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Tertatolol.]
[N06AX14, tianeptine, Tianeptine may decrease the hypoglycemic activities of Dapagliflozin.]
[C09AA02, enalapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Enalapril.]
[N06AG03, toloxatone, Toloxatone may increase the orthostatic hypotensive activities of Dapagliflozin.]
[N06BA09, atomoxetine, Dapagliflozin may increase the excretion rate of Atomoxetine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AX11, topiramate, Dapagliflozin may increase the excretion rate of Topiramate which could result in a lower serum level and potentially a reduction in efficacy.]
[C03CA04, torsemide, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Torasemide.]
[C09AA10, trandolapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Trandolapril.]
[N05CC01, chloral hydrate, Dapagliflozin may increase the excretion rate of Chloral hydrate which could result in a lower serum level and potentially a reduction in efficacy.]
[H02CA01, trilostane, The risk or severity of hyperglycemia can be increased when Trilostane is combined with Dapagliflozin.]
[L02AE04, triptorelin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Triptorelin.]
[C02CA06, urapidil, Dapagliflozin may increase the hypotensive activities of Urapidil.]
[J01MA04, enoxacin, The metabolism of Dapagliflozin can be decreased when combined with Enoxacin.]
[L01CA04, vinorelbine, The metabolism of Dapagliflozin can be decreased when combined with Vinorelbine.]
[S01FB02, ephedrine, The risk or severity of Cardiac Arrhythmia can be increased when Ephedrine is combined with Dapagliflozin.]
[S01GX10, epinastine, The metabolism of Dapagliflozin can be decreased when combined with Epinastine.]
[N06AX16, venlafaxine, The metabolism of Dapagliflozin can be decreased when combined with Venlafaxine.]
[S01GA03, xylometazoline, The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Dapagliflozin.]
[C08CA12, mepirodipine, The metabolism of Dapagliflozin can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Epinephrine.]
[C09AA15, zofenopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Zofenopril.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be decreased when combined with Dapagliflozin.]
[N03AX15, zonisamide, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Zonisamide.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Dapagliflozin is combined with Insulin glulisine.]
[N05CF01, zopiclone, The metabolism of Dapagliflozin can be decreased when combined with Zopiclone.]
[N05AX11, zotepine, The metabolism of Zotepine can be decreased when combined with Dapagliflozin.]
[L01XA02, carboplatin, Dapagliflozin may increase the excretion rate of Carboplatin which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AC02, guanfacine, Dapagliflozin may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC11, iloprost, The risk or severity of adverse effects can be increased when Iloprost is combined with Dapagliflozin.]
[N02CA02, ergotamine, The metabolism of Dapagliflozin can be decreased when combined with Ergotamine.]
[L03AX05, pidotimod, Dapagliflozin may increase the excretion rate of Pidotimod which could result in a lower serum level and potentially a reduction in efficacy.]
[S01AA17, erythromycin, The metabolism of Dapagliflozin can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, Dapagliflozin may increase the excretion rate of Estazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BC02, pantoprazole, Dapagliflozin may increase the excretion rate of Pantoprazole which could result in a lower serum level and potentially a reduction in efficacy.]
[H05BX01, cinacalcet, The metabolism of Dapagliflozin can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Estradiol.]
[G03CA57, estrogens, conjugated (USP), Dapagliflozin may increase the excretion rate of Conjugated estrogens which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK02, ethambutol, Dapagliflozin may increase the excretion rate of Ethambutol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA09, fluticasone furoate, The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Dapagliflozin.]
[R03BA05, fluticasone, The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Dapagliflozin.]
[C10AA04, fluvastatin, The metabolism of Dapagliflozin can be decreased when combined with Fluvastatin.]
[V08CA03, gadodiamide, Dapagliflozin may increase the excretion rate of Gadodiamide which could result in a lower serum level and potentially a reduction in efficacy.]
[D07AC21, halobetasol, The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Dapagliflozin.]
[L02AA03, ethinyl estradiol, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Ethinylestradiol.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Amifostine is combined with Dapagliflozin.]
[C01BD05, ibutilide, Dapagliflozin may increase the excretion rate of Ibutilide which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AD01, ethosuximide, The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Dapagliflozin.]
[M01AC06, meloxicam, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Meloxicam.]
[S01XA06, ethylmorphine, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Ethylmorphine.]
[N01AX07, etomidate, Dapagliflozin may increase the excretion rate of Etomidate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Dapagliflozin.]
[N05AE03, sertindole, The metabolism of Dapagliflozin can be decreased when combined with Sertindole.]
[L04AD02, tacrolimus, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Tacrolimus.]
[J01MA08, fleroxacin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Fleroxacin.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Dapagliflozin.]
[R06AX12, terfenadine, The metabolism of Dapagliflozin can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Dapagliflozin may increase the excretion rate of Trimetrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX12, bupropion, The metabolism of Dapagliflozin can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Dapagliflozin can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, The metabolism of Tocainide can be decreased when combined with Dapagliflozin.]
[C01BC08, encainide, The metabolism of Dapagliflozin can be decreased when combined with Encainide.]
[L02AE02, leuprolide, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Leuprolide.]
[M01CB01, gold sodium thiomalate, Dapagliflozin may increase the excretion rate of Sodium aurothiomalate which could result in a lower serum level and potentially a reduction in efficacy.]
[A05AA01, chenodeoxycholic acid, The metabolism of Dapagliflozin can be decreased when combined with Chenodeoxycholic acid.]
[B05AA05, dextran, Dapagliflozin may increase the excretion rate of Dextran which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AF02, dexrazoxane, Dapagliflozin may increase the excretion rate of Dexrazoxane which could result in a lower serum level and potentially a reduction in efficacy.]
[A02BA03, famotidine, The metabolism of Dapagliflozin can be decreased when combined with Famotidine.]
[A16AA01, levocarnitine, Dapagliflozin may increase the excretion rate of Levocarnitine which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA03, albendazole, The metabolism of Dapagliflozin can be increased when combined with Albendazole.]
[C08CA02, felodipine, The metabolism of Dapagliflozin can be decreased when combined with Felodipine.]
[C08EA01, fendiline, The risk or severity of hypoglycemia can be increased when Fendiline is combined with Dapagliflozin.]
[N03AX26, fenfluramine, The metabolism of Dapagliflozin can be decreased when combined with Fenfluramine.]
[N02AB03, fentanyl, Dapagliflozin may increase the excretion rate of Fentanyl which could result in a lower serum level and potentially a reduction in efficacy.]
[R03CC02, albuterol, Dapagliflozin may increase the excretion rate of Salbutamol which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BB06, clofarabine, Dapagliflozin may increase the excretion rate of Clofarabine which could result in a lower serum level and potentially a reduction in efficacy.]
[N07AX03, cevimeline, Dapagliflozin may increase the excretion rate of Cevimeline which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD02, flavoxate, Dapagliflozin may increase the excretion rate of Flavoxate which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Dapagliflozin.]
[J02AC01, fluconazole, The risk or severity of hypoglycemia can be increased when Dapagliflozin is combined with Fluconazole.]
[J02AX01, flucytosine, Dapagliflozin may increase the excretion rate of Flucytosine which could result in a lower serum level and potentially a reduction in efficacy.]
[H02AA02, fludrocortisone, The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Dapagliflozin.]
[V03AB25, flumazenil, Dapagliflozin may increase the excretion rate of Flumazenil which could result in a lower serum level and potentially a reduction in efficacy.]
[D07XB01, flumethasone, The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Dapagliflozin.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be decreased when combined with Dapagliflozin.]
[N05CD03, flunitrazepam, The metabolism of Dapagliflozin can be decreased when combined with Flunitrazepam.]
[D07AC08, fluocinonide, The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Dapagliflozin.]
[N06AA14, melitracen, Melitracen may decrease the hypoglycemic activities of Dapagliflozin.]
[H02AB03, fluocortolone, The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Dapagliflozin.]
[V03AZ01, ethanol, Ethanol may increase the hypotensive activities of Dapagliflozin.]
[L01BC09, floxuridine, The metabolism of Dapagliflozin can be decreased when combined with Floxuridine.]
[S01CB05, fluorometholone, The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Dapagliflozin.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Dapagliflozin.]
[N06AB03, fluoxetine, The serum concentration of Dapagliflozin can be increased when it is combined with Fluoxetine.]
[G03BA01, fluoxymesterone, Fluoxymesterone may increase the hypoglycemic activities of Dapagliflozin.]
[N05AB02, fluphenazine, The metabolism of Dapagliflozin can be decreased when combined with Fluphenazine.]
[D07AC07, flurandrenolide, The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Dapagliflozin.]
[N05CD01, flurazepam, Dapagliflozin may increase the excretion rate of Flurazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC04, flurbiprofen, Dapagliflozin may increase the excretion rate of Flurbiprofen which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AG01, fluspirilene, The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Dapagliflozin.]
[L02BB01, flutamide, Dapagliflozin may increase the excretion rate of Flutamide which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CX02, folic acid, Dapagliflozin may increase the excretion rate of Folic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[S02AA17, fosfomycin, Dapagliflozin may increase the excretion rate of Fosfomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Dapagliflozin.]
[G01AX06, furazolidone, Furazolidone may increase the orthostatic hypotensive activities of Dapagliflozin.]
[J05AE10, darunavir, The metabolism of Dapagliflozin can be decreased when combined with Darunavir.]
[C03CA01, furosemide, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Furosemide.]
[N05CF04, eszopiclone, Dapagliflozin may increase the excretion rate of Eszopiclone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06DA04, galantamine, The metabolism of Dapagliflozin can be decreased when combined with Galantamine.]
[C08DA02, gallopamil, The risk or severity of hypoglycemia can be increased when Gallopamil is combined with Dapagliflozin.]
[S01AD09, ganciclovir, Dapagliflozin may increase the excretion rate of Ganciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Dapagliflozin.]
[C10AB04, gemfibrozil, The metabolism of Dapagliflozin can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, Dapagliflozin may increase the excretion rate of Telavancin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Dapagliflozin.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Dapagliflozin.]
[A10BJ02, liraglutide, Dapagliflozin may increase the hypoglycemic activities of Liraglutide.]
[J05AG04, etravirine, The metabolism of Dapagliflozin can be decreased when combined with Etravirine.]
[N03AD03, methsuximide, The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Dapagliflozin.]
[N01AH02, alfentanil, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Alfentanil.]
[A10BB01, glyburide, Dapagliflozin may increase the hypoglycemic activities of Glyburide.]
[A10BB09, gliclazide, Dapagliflozin may increase the hypoglycemic activities of Gliclazide.]
[A10BB07, glipizide, Dapagliflozin may increase the hypoglycemic activities of Glipizide.]
[N05CM18, dexmedetomidine, Dapagliflozin may increase the excretion rate of Dexmedetomidine which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX01, glycerin, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Glycerin.]
[C05AE01, nitroglycerin, The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Dapagliflozin.]
[C02CA04, doxazosin, The risk or severity of adverse effects can be increased when Doxazosin is combined with Dapagliflozin.]
[H01AB01, thyrotropin alfa, Thyrotropin alfa may decrease the hypoglycemic activities of Dapagliflozin.]
[L01EX02, sorafenib, The metabolism of Dapagliflozin can be decreased when combined with Sorafenib.]
[C07AB09, esmolol, The risk or severity of adverse effects can be increased when Esmolol is combined with Dapagliflozin.]
[M01CB04, aurothioglucose, Dapagliflozin may increase the excretion rate of Aurothioglucose which could result in a lower serum level and potentially a reduction in efficacy.]
[S01LA03, pegaptanib, Dapagliflozin may increase the excretion rate of Pegaptanib which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AA12, fluindione, The metabolism of Fluindione can be decreased when combined with Dapagliflozin.]
[C09AA09, fosinopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Fosinopril.]
[S01EX01, guanethidine, Dapagliflozin may increase the excretion rate of Guanethidine which could result in a lower serum level and potentially a reduction in efficacy.]
[L02AE03, goserelin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Goserelin.]
[P01BX01, halofantrine, The metabolism of Dapagliflozin can be decreased when combined with Halofantrine.]
[D07AD02, halcinonide, The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Dapagliflozin.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Dapagliflozin.]
[N01AB01, halothane, The metabolism of Dapagliflozin can be decreased when combined with Halothane.]
[L02AE05, histrelin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Histrelin.]
[N05AH04, quetiapine, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Quetiapine.]
[N06BX13, idebenone, Dapagliflozin may increase the excretion rate of Idebenone which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Dapagliflozin is combined with Insulin aspart.]
[M04AA01, allopurinol, Dapagliflozin may increase the excretion rate of Allopurinol which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA01, losartan, The risk or severity of adverse effects can be increased when Losartan is combined with Dapagliflozin.]
[B05CB03, magnesium citrate, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Magnesium citrate.]
[G03DC01, allylestrenol, Dapagliflozin may increase the excretion rate of Allylestrenol which could result in a lower serum level and potentially a reduction in efficacy.]
[A07EC02, mesalamine, Mesalazine may increase the hypoglycemic activities of Dapagliflozin.]
[C01CE02, milrinone, Dapagliflozin may increase the excretion rate of Milrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[A12CD02, sodium monofluorophosphate, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Sodium fluorophosphate.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Dapagliflozin.]
[J05AG01, nevirapine, The metabolism of Dapagliflozin can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Dapagliflozin can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypoglycemia can be increased when Nimesulide is combined with Dapagliflozin.]
[C09AA04, perindopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Perindopril.]
[C02DB02, hydralazine, Dapagliflozin may increase the excretion rate of Hydralazine which could result in a lower serum level and potentially a reduction in efficacy.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Hydrochlorothiazide.]
[R05DA03, hydrocodone, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Hydrocodone.]
[S02BA01, hydrocortisone, The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Dapagliflozin.]
[D07AC16, hydrocortisone aceponate, The risk or severity of hyperglycemia can be increased when Hydrocortisone aceponate is combined with Dapagliflozin.]
[D07AB11, hydrocortisone probutate, The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Dapagliflozin.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Hydroflumethiazide.]
[B05XA17, potassium acetate, Dapagliflozin may increase the excretion rate of Potassium acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Dapagliflozin may increase the excretion rate of Hydroxocobalamin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BD06, propiverine, Dapagliflozin may increase the excretion rate of Propiverine which could result in a lower serum level and potentially a reduction in efficacy.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Hydroxychloroquine.]
[B05AA07, hetastarch, Dapagliflozin may increase the excretion rate of Hydroxyethyl Starch which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BB01, hydroxyzine, The metabolism of Dapagliflozin can be decreased when combined with Hydroxyzine.]
[C02AC06, rilmenidine, Dapagliflozin may increase the hypotensive activities of Rilmenidine.]
[S01BA13, rimexolone, The risk or severity of hyperglycemia can be increased when Rimexolone is combined with Dapagliflozin.]
[R02AX02, ibuprofen, Dapagliflozin may increase the excretion rate of Ibuprofen which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA08, sodium acetate, Dapagliflozin may increase the excretion rate of Sodium acetate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01DB06, idarubicin, The metabolism of Dapagliflozin can be decreased when combined with Idarubicin.]
[A06AD21, sodium tartrate, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Sodium tartrate.]
[L01AA06, ifosfamide, Dapagliflozin may increase the excretion rate of Ifosfamide which could result in a lower serum level and potentially a reduction in efficacy.]
[H01AC02, somatrem, Somatrem may decrease the hypoglycemic activities of Dapagliflozin.]
[N01AH03, sufentanil, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Sufentanil.]
[N06AA02, imipramine, The metabolism of Dapagliflozin can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Paclitaxel is combined with Dapagliflozin.]
[R01AD07, tixocortol, The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Dapagliflozin.]
[M03BX02, tizanidine, The metabolism of Tizanidine can be decreased when combined with Dapagliflozin.]
[L01CE01, topotecan, Dapagliflozin may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA11, indapamide, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Indapamide.]
[S01BC01, indomethacin, The risk or severity of hypoglycemia can be increased when Indomethacin is combined with Dapagliflozin.]
[C02CA02, indoramin, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Indoramin.]
[A11HA07, inositol, Dapagliflozin may increase the excretion rate of Inositol which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AB04, interferon alfa-2a, The metabolism of Dapagliflozin can be decreased when combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The metabolism of Dapagliflozin can be decreased when combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The risk or severity of hypoglycemia can be increased when Milnacipran is combined with Dapagliflozin.]
[S01XA28, varenicline, Dapagliflozin may increase the excretion rate of Varenicline which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB08, articaine, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Articaine.]
[A10BH01, sitagliptin, Dapagliflozin may increase the hypoglycemic activities of Sitagliptin.]
[N05BA12, alprazolam, Dapagliflozin may increase the excretion rate of Alprazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH02, ramelteon, Dapagliflozin may increase the excretion rate of Ramelteon which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BH02, vildagliptin, Dapagliflozin may increase the hypoglycemic activities of Vildagliptin.]
[C10AA06, cerivastatin, The metabolism of Dapagliflozin can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The metabolism of Anagrelide can be decreased when combined with Dapagliflozin.]
[C07AA01, alprenolol, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Alprenolol.]
[C03BA02, quinethazone, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Quinethazone.]
[L03AB09, interferon alfacon-1, The metabolism of Dapagliflozin can be decreased when combined with Interferon alfacon-1.]
[V03AB01, ipecac, Dapagliflozin may increase the excretion rate of Ipecac which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA13, iprindole, Iprindole may decrease the hypoglycemic activities of Dapagliflozin.]
[N06AF05, iproniazid, Iproniazid may increase the orthostatic hypotensive activities of Dapagliflozin.]
[J05AB13, penciclovir, The metabolism of Penciclovir can be decreased when combined with Dapagliflozin.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the orthostatic hypotensive activities of Dapagliflozin.]
[P01AX06, atovaquone, The metabolism of Dapagliflozin can be decreased when combined with Atovaquone.]
[C09AA16, imidapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Dapagliflozin.]
[N04BX02, entacapone, The metabolism of Dapagliflozin can be decreased when combined with Entacapone.]
[J04AC01, isoniazid, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Isoniazid.]
[J05AX05, inosine pranobex, Dapagliflozin may increase the excretion rate of Inosine pranobex which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BJ01, exenatide, Dapagliflozin may increase the hypoglycemic activities of Exenatide.]
[C01DA14, isosorbide mononitrate, Dapagliflozin may increase the excretion rate of Isosorbide mononitrate which could result in a lower serum level and potentially a reduction in efficacy.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Dapagliflozin.]
[D10BA01, isotretinoin, Dapagliflozin may increase the excretion rate of Isotretinoin which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AA01, isoxsuprine, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Isoxsuprine.]
[N06AX18, reboxetine, The metabolism of Dapagliflozin can be decreased when combined with Reboxetine.]
[H01AC01, somatropin, Somatotropin may decrease the hypoglycemic activities of Dapagliflozin.]
[L04AC07, tocilizumab, The metabolism of Dapagliflozin can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Dapagliflozin may increase the excretion rate of Ketamine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02KD01, ketanserin, Dapagliflozin may increase the hypotensive activities of Ketanserin.]
[B01AC22, prasugrel, Dapagliflozin may increase the excretion rate of Prasugrel which could result in a lower serum level and potentially a reduction in efficacy.]
[J02AB02, ketoconazole, The metabolism of Dapagliflozin can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Dapagliflozin can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Olanzapine.]
[M02AA10, ketoprofen, Dapagliflozin may increase the excretion rate of Ketoprofen which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC03, deferasirox, The serum concentration of Dapagliflozin can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Dapagliflozin can be increased when combined with Abatacept.]
[S01GX08, ketotifen, The risk or severity of thrombocytopenia can be increased when Dapagliflozin is combined with Ketotifen.]
[N04BC09, rotigotine, The metabolism of Dapagliflozin can be decreased when combined with Rotigotine.]
[A16AX01, thioctic acid, The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Dapagliflozin.]
[D10AX03, azelaic acid, Dapagliflozin may increase the excretion rate of Azelaic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MB02, nalidixic acid, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Nalidixic acid.]
[C07AG01, labetalol, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Labetalol.]
[N04BB01, amantadine, Dapagliflozin may increase the excretion rate of Amantadine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA05, deserpidine, Dapagliflozin may increase the hypotensive activities of Deserpidine.]
[A06AD11, lactulose, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Lactulose.]
[A06AX03, lubiprostone, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Lubiprostone.]
[N03AX18, lacosamide, The metabolism of Dapagliflozin can be decreased when combined with Lacosamide.]
[C03CC01, ethacrynic acid, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Etacrynic acid.]
[G03AD01, levonorgestrel, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Levonorgestrel.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Dapagliflozin is combined with Levodopa.]
[S02DA01, lidocaine, The metabolism of Dapagliflozin can be decreased when combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of hypoglycemia can be increased when Lidoflazine is combined with Dapagliflozin.]
[N06BA13, armodafinil, The metabolism of Dapagliflozin can be increased when combined with Armodafinil.]
[C03DB01, amiloride, The risk or severity of adverse effects can be increased when Amiloride is combined with Dapagliflozin.]
[N02CA07, lisuride, The metabolism of Dapagliflozin can be decreased when combined with Lisuride.]
[N06AA07, lofepramine, Lofepramine may decrease the hypoglycemic activities of Dapagliflozin.]
[A07DA03, loperamide, The risk or severity of hypoglycemia can be increased when Loperamide is combined with Dapagliflozin.]
[N05BA06, lorazepam, Dapagliflozin may increase the excretion rate of Lorazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AA02, lovastatin, The metabolism of Dapagliflozin can be decreased when combined with Lovastatin.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be decreased when combined with Dapagliflozin.]
[L01EG01, temsirolimus, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Temsirolimus.]
[B05XA11, magnesium chloride, Dapagliflozin may increase the excretion rate of Magnesium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BX01, magnesium hydroxide, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Magnesium oxide.]
[V04CC02, magnesium sulfate, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Magnesium sulfate.]
[L01BA05, pralatrexate, Dapagliflozin may increase the excretion rate of Pralatrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EA03, nilotinib, The metabolism of Dapagliflozin can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Mannitol.]
[N06AA21, maprotiline, Dapagliflozin may increase the excretion rate of Maprotiline which could result in a lower serum level and potentially a reduction in efficacy.]
[C02BB01, mecamylamine, Dapagliflozin may increase the excretion rate of Mecamylamine which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AE05, meclizine, The metabolism of Dapagliflozin can be decreased when combined with Meclizine.]
[M02AA18, meclofenamic acid, Dapagliflozin may increase the excretion rate of Meclofenamic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AB07, cascara sagrada, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Frangula purshiana bark.]
[C03BA05, mefruside, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Mefruside.]
[N05CH01, melatonin, The metabolism of Melatonin can be decreased when combined with Dapagliflozin.]
[N06DX01, memantine, Dapagliflozin may increase the excretion rate of Memantine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AB02, meperidine, Dapagliflozin may increase the excretion rate of Meperidine which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Dapagliflozin.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Dapagliflozin.]
[N01BB03, mepivacaine, Dapagliflozin may increase the excretion rate of Mepivacaine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AX05, meptazinol, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Meptazinol.]
[G04BX16, tiopronin, Dapagliflozin may increase the excretion rate of Tiopronin which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BC01, mersalyl, Dapagliflozin may increase the excretion rate of Mersalyl which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The metabolism of Dapagliflozin can be decreased when combined with Mesoridazine.]
[G03BB01, mesterolone, Mesterolone may increase the hypoglycemic activities of Dapagliflozin.]
[N05AX13, paliperidone, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Paliperidone.]
[A04AA04, dolasetron, The metabolism of Dapagliflozin can be decreased when combined with Dolasetron.]
[H01CB03, lanreotide, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Lanreotide.]
[N07BC02, methadone, Dapagliflozin may increase the excretion rate of Methadone which could result in a lower serum level and potentially a reduction in efficacy.]
[N06BA03, methamphetamine, Dapagliflozin may increase the excretion rate of Metamfetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF05, lamivudine, Dapagliflozin may increase the excretion rate of Lamivudine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EC05, methazolamide, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Methazolamide.]
[H03BB02, methimazole, The metabolism of Dapagliflozin can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Dapagliflozin may increase the excretion rate of Pemetrexed which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Dapagliflozin.]
[A11HA02, pyridoxine, Dapagliflozin may increase the excretion rate of Pyridoxine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Dapagliflozin is combined with Ziconotide.]
[L04AX03, methotrexate, Dapagliflozin may increase the excretion rate of Methotrexate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AA02, methotrimeprazine, The metabolism of Dapagliflozin can be decreased when combined with Methotrimeprazine.]
[D05BA02, methoxsalen, Dapagliflozin may increase the excretion rate of Methoxsalen which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BG09, methoxyflurane, The metabolism of Dapagliflozin can be decreased when combined with Methoxyflurane.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Methyclothiazide.]
[A06AC06, methylcellulose, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Methylcellulose.]
[C02AB01, methyldopa, Dapagliflozin may increase the excretion rate of Methyldopa which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CG05, methylene blue, Methylene blue may increase the orthostatic hypotensive activities of Dapagliflozin.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Dapagliflozin.]
[H02AB04, methylprednisolone, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Dapagliflozin.]
[D07AC14, methylprednisolone aceponate, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Dapagliflozin.]
[G03EK01, methyltestosterone, Dapagliflozin may increase the excretion rate of Methyltestosterone which could result in a lower serum level and potentially a reduction in efficacy.]
[A03FA01, metoclopramide, Dapagliflozin may increase the excretion rate of Metoclopramide which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA08, metolazone, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Metolazone.]
[C07AB02, metoprolol, The metabolism of Dapagliflozin can be decreased when combined with Metoprolol.]
[P01AB01, metronidazole, The metabolism of Dapagliflozin can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, Dapagliflozin may increase the excretion rate of Metyrapone which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BB02, mexiletine, The metabolism of Dapagliflozin can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Dapagliflozin.]
[S02AA13, miconazole, The metabolism of Dapagliflozin can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Dapagliflozin.]
[N05CD08, midazolam, Dapagliflozin may increase the excretion rate of Midazolam which could result in a lower serum level and potentially a reduction in efficacy.]
[G03XB01, mifepristone, Dapagliflozin may increase the hypoglycemic activities of Mifepristone.]
[A06AA01, mineral oil, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Mineral oil.]
[J05AH01, zanamivir, Dapagliflozin may increase the excretion rate of Zanamivir which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA03, valsartan, The metabolism of Dapagliflozin can be decreased when combined with Valsartan.]
[D11AX01, minoxidil, The risk or severity of adverse effects can be increased when Minoxidil is combined with Dapagliflozin.]
[L01XX23, mitotane, The metabolism of Dapagliflozin can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The metabolism of Dapagliflozin can be decreased when combined with Lisdexamfetamine.]
[L03AC01, aldesleukin, Dapagliflozin may increase the excretion rate of Aldesleukin which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BD01, amiodarone, The metabolism of Dapagliflozin can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Dapagliflozin.]
[N02AA01, morphine, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Morphine.]
[A04AA05, palonosetron, Dapagliflozin may increase the excretion rate of Palonosetron which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AB05, certolizumab pegol, The metabolism of Dapagliflozin can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Dapagliflozin.]
[G04BA01, ammonium chloride, Dapagliflozin may increase the excretion rate of Ammonium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Dapagliflozin.]
[L04AA06, mycophenolic acid, Dapagliflozin may increase the excretion rate of Mycophenolic acid which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Dapagliflozin.]
[P01BA06, amodiaquine, The metabolism of Dapagliflozin can be decreased when combined with Amodiaquine.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Dapagliflozin.]
[N03AB05, fosphenytoin, The metabolism of Dapagliflozin can be increased when combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The metabolism of Dapagliflozin can be decreased when combined with Interferon beta-1b.]
[C07AA12, nadolol, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Nadolol.]
[J01CA04, amoxicillin, Dapagliflozin may increase the excretion rate of Amoxicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Ropinirole.]
[J01CF06, nafcillin, The metabolism of Dapagliflozin can be increased when combined with Nafcillin.]
[N02AF02, nalbuphine, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Dapagliflozin can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Naltrexone.]
[L04AC03, anakinra, The metabolism of Dapagliflozin can be increased when combined with Anakinra.]
[S01XA11, nandrolone, Nandrolone phenpropionate may increase the hypoglycemic activities of Dapagliflozin.]
[N06BA01, amphetamine, Dapagliflozin may increase the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA12, naproxen, The metabolism of Naproxen can be decreased when combined with Dapagliflozin.]
[A10BG01, troglitazone, Dapagliflozin may increase the hypoglycemic activities of Troglitazone.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Dapagliflozin is combined with Duloxetine.]
[N04BX01, tolcapone, Dapagliflozin may increase the excretion rate of Tolcapone which could result in a lower serum level and potentially a reduction in efficacy.]
[L02BG04, letrozole, The metabolism of Dapagliflozin can be decreased when combined with Letrozole.]
[N01AH06, remifentanil, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Remifentanil.]
[A10BX02, repaglinide, Dapagliflozin may increase the hypoglycemic activities of Repaglinide.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Levosimendan is combined with Dapagliflozin.]
[B01AC17, tirofiban, Dapagliflozin may increase the excretion rate of Tirofiban which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AX14, iloperidone, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Dapagliflozin.]
[S01AA19, ampicillin, Dapagliflozin may increase the excretion rate of Ampicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[L03AX16, plerixafor, Dapagliflozin may increase the excretion rate of Plerixafor which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AX23, desvenlafaxine, The risk or severity of hypoglycemia can be increased when Desvenlafaxine is combined with Dapagliflozin.]
[C09CA07, telmisartan, The risk or severity of adverse effects can be increased when Telmisartan is combined with Dapagliflozin.]
[J05AB11, valacyclovir, Dapagliflozin may increase the excretion rate of Valaciclovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CE01, inamrinone, Dapagliflozin may increase the excretion rate of Amrinone which could result in a lower serum level and potentially a reduction in efficacy.]
[C10AD02, niacin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Niacin.]
[N06AF02, nialamide, Nialamide may increase the orthostatic hypotensive activities of Dapagliflozin.]
[C08CA04, nicardipine, The metabolism of Dapagliflozin can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, The metabolism of Dapagliflozin can be decreased when combined with Nicergoline.]
[P02DA01, niclosamide, The metabolism of Dapagliflozin can be decreased when combined with Niclosamide.]
[N07BA01, nicotine, The metabolism of Dapagliflozin can be decreased when combined with Nicotine.]
[C08CA05, nifedipine, Dapagliflozin may increase the excretion rate of Nifedipine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA17, niflumic acid, The metabolism of Dapagliflozin can be decreased when combined with Niflumic acid.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Dapagliflozin.]
[C08CA06, nimodipine, The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Dapagliflozin.]
[C08CA07, nisoldipine, Dapagliflozin may increase the excretion rate of Nisoldipine which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA08, nitrendipine, The risk or severity of hypoglycemia can be increased when Nitrendipine is combined with Dapagliflozin.]
[R07AX01, nitric oxide, Dapagliflozin may increase the excretion rate of Nitric Oxide which could result in a lower serum level and potentially a reduction in efficacy.]
[J01XE01, nitrofurantoin, Dapagliflozin may increase the excretion rate of Nitrofurantoin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF03, zaleplon, Dapagliflozin may increase the excretion rate of Zaleplon which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BC05, pramipexole, Dapagliflozin may increase the excretion rate of Pramipexole which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DD01, nitroprusside, Dapagliflozin may increase the excretion rate of Nitroprusside which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA03, norepinephrine, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Dapagliflozin.]
[G03DC02, norethindrone, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Norethisterone.]
[S01AE02, norfloxacin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Norfloxacin.]
[C02KX01, bosentan, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Dapagliflozin.]
[R05DA07, noscapine, The metabolism of Dapagliflozin can be decreased when combined with Noscapine.]
[L03AB07, interferon beta-1a, The metabolism of Dapagliflozin can be decreased when combined with Interferon beta-1a.]
[G02CA02, nylidrin, The risk or severity of hypoglycemia can be increased when Nylidrin is combined with Dapagliflozin.]
[H01CB02, octreotide, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Octreotide.]
[S02AA16, ofloxacin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Ofloxacin.]
[L04AC04, rilonacept, The metabolism of Dapagliflozin can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Dapagliflozin can be increased when combined with Omeprazole.]
[N06AA05, opipramol, Opipramol may decrease the hypoglycemic activities of Dapagliflozin.]
[N02AA02, opium, Dapagliflozin may increase the excretion rate of Opium which could result in a lower serum level and potentially a reduction in efficacy.]
[G04CA02, tamsulosin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Tamsulosin.]
[J01CF04, oxacillin, Dapagliflozin may increase the excretion rate of Oxacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[P02BA02, oxamniquine, The metabolism of Dapagliflozin can be decreased when combined with Oxamniquine.]
[A14AA08, oxandrolone, The metabolism of Dapagliflozin can be decreased when combined with Oxandrolone.]
[N05BA04, oxazepam, Dapagliflozin may increase the excretion rate of Oxazepam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MB05, oxolinic acid, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Oxolinic acid.]
[C07AA02, oxprenolol, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Oxprenolol.]
[N02AA05, oxycodone, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Oxycodone.]
[A14AA05, oxymetholone, Oxymetholone may increase the hypoglycemic activities of Dapagliflozin.]
[N02AA11, oxymorphone, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Oxymorphone.]
[J04AA01, aminosalicylic acid, Aminosalicylic acid may increase the hypoglycemic activities of Dapagliflozin.]
[N05AH05, asenapine, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Asenapine.]
[N02AX06, tapentadol, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Tapentadol.]
[J04AB30, capreomycin, Dapagliflozin may increase the excretion rate of Capreomycin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Papaverine is combined with Dapagliflozin.]
[H02AB05, paramethasone, The risk or severity of hyperglycemia can be increased when Paramethasone is combined with Dapagliflozin.]
[C02KC01, pargyline, Pargyline may increase the orthostatic hypotensive activities of Dapagliflozin.]
[J01MA03, pefloxacin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Pefloxacin.]
[G04BD11, fesoterodine, Dapagliflozin may increase the excretion rate of Fesoterodine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AA23, penbutolol, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of hypoglycemia can be increased when Penfluridol is combined with Dapagliflozin.]
[J01CE09, penicillin G procaine, Dapagliflozin may increase the excretion rate of Procaine benzylpenicillin which could result in a lower serum level and potentially a reduction in efficacy.]
[N02AD01, pentazocine, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Pentazocine.]
[N05CA01, pentobarbital, The metabolism of Dapagliflozin can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Dapagliflozin may increase the excretion rate of Pentostatin which could result in a lower serum level and potentially a reduction in efficacy.]
[C04AD03, pentoxifylline, Dapagliflozin may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[C08EX02, perhexiline, The metabolism of Dapagliflozin can be decreased when combined with Perhexiline.]
[N05AB03, perphenazine, The metabolism of Dapagliflozin can be decreased when combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Dapagliflozin.]
[N02AD02, phenazocine, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Phenazocine.]
[G04BX06, phenazopyridine, Dapagliflozin may increase the excretion rate of Phenazopyridine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AF03, phenelzine, Phenelzine may increase the orthostatic hypotensive activities of Dapagliflozin.]
[A10BA01, phenformin, Dapagliflozin may increase the hypoglycemic activities of Phenformin.]
[N03AA02, phenobarbital, The metabolism of Dapagliflozin can be increased when combined with Phenobarbital.]
[A06AB01, oxyphenisatin, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Oxyphenisatin.]
[N01AH04, phenoperidine, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Phenoperidine.]
[C04AX02, phenoxybenzamine, The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Dapagliflozin.]
[B01AA04, phenprocoumon, The metabolism of Dapagliflozin can be decreased when combined with Phenprocoumon.]
[A08AA01, phentermine, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Phentermine.]
[V03AB36, phentolamine, Dapagliflozin may increase the excretion rate of Phentolamine which could result in a lower serum level and potentially a reduction in efficacy.]
[M02AA01, phenylbutazone, The metabolism of Dapagliflozin can be decreased when combined with Phenylbutazone.]
[S01GA05, phenylephrine, The metabolism of Dapagliflozin can be increased when combined with Phenylephrine.]
[N03AB02, phenytoin, The metabolism of Dapagliflozin can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Dapagliflozin can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Levofloxacin.]
[B02BA01, vitamin K1, Dapagliflozin may increase the excretion rate of Phylloquinone which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AB12, cidofovir, Dapagliflozin may increase the excretion rate of Cidofovir which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CX01, mibefradil, The metabolism of Dapagliflozin can be decreased when combined with Mibefradil.]
[S01EB01, pilocarpine, The metabolism of Dapagliflozin can be decreased when combined with Pilocarpine.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Dapagliflozin.]
[C07AA03, pindolol, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Pindolol.]
[J01CA12, piperacillin, Dapagliflozin may increase the excretion rate of Piperacillin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE01, saquinavir, The metabolism of Dapagliflozin can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Piperazine.]
[N05AC04, pipothiazine, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Pipotiazine.]
[N06BX03, piracetam, Dapagliflozin may increase the excretion rate of Piracetam which could result in a lower serum level and potentially a reduction in efficacy.]
[C09CA02, eprosartan, The risk or severity of adverse effects can be increased when Eprosartan is combined with Dapagliflozin.]
[N02AC03, pirinitramide, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Piritramide.]
[S01BC06, piroxicam, Dapagliflozin may increase the excretion rate of Piroxicam which could result in a lower serum level and potentially a reduction in efficacy.]
[J01MA11, grepafloxacin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Grepafloxacin.]
[J05AG02, delavirdine, The metabolism of Dapagliflozin can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The risk or severity of adverse effects can be increased when Irbesartan is combined with Dapagliflozin.]
[A10BG02, rosiglitazone, Dapagliflozin may increase the hypoglycemic activities of Rosiglitazone.]
[A06AD15, polyethylene glycols, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Polyethylene glycol.]
[A03AE01, alosetron, The metabolism of Dapagliflozin can be decreased when combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Dapagliflozin can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Dapagliflozin can be increased when it is combined with Ritonavir.]
[B05XA01, potassium chloride, Dapagliflozin may increase the excretion rate of Potassium chloride which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Dapagliflozin is combined with Insulin lispro.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Dapagliflozin.]
[C07AB01, practolol, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Practolol.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Dapagliflozin.]
[C02CA01, prazosin, The risk or severity of adverse effects can be increased when Prazosin is combined with Dapagliflozin.]
[S03BA02, prednisolone, The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Dapagliflozin.]
[H02AB07, prednisone, The risk or severity of hyperglycemia can be increased when Prednisone is combined with Dapagliflozin.]
[C01DX02, prenylamine, The risk or severity of hypoglycemia can be increased when Prenylamine is combined with Dapagliflozin.]
[P01BA03, primaquine, The metabolism of Dapagliflozin can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Dapagliflozin can be increased when combined with Primidone.]
[M04AB01, probenecid, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Probenecid.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Dapagliflozin.]
[S01HA05, procaine, Procaine may increase the orthostatic hypotensive activities of Dapagliflozin.]
[L01XB01, procarbazine, Procarbazine may increase the orthostatic hypotensive activities of Dapagliflozin.]
[C10AB05, fenofibrate, Dapagliflozin may increase the excretion rate of Fenofibrate which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AB04, prochlorperazine, The metabolism of Dapagliflozin can be decreased when combined with Prochlorperazine.]
[G03DA04, progesterone, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Progesterone.]
[N05AA03, promazine, The metabolism of Dapagliflozin can be decreased when combined with Promazine.]
[R06AD02, promethazine, Dapagliflozin may increase the excretion rate of Promethazine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01BC03, propafenone, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Propafenone.]
[A03AB05, propantheline, Dapagliflozin may increase the excretion rate of Propantheline which could result in a lower serum level and potentially a reduction in efficacy.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Dapagliflozin.]
[N02AC04, propoxyphene, The metabolism of Dapagliflozin can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Propranolol.]
[N02CC04, rizatriptan, Dapagliflozin may increase the excretion rate of Rizatriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AC09, epoprostenol, Dapagliflozin may increase the excretion rate of Epoprostenol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DC03, montelukast, The metabolism of Dapagliflozin can be decreased when combined with Montelukast.]
[N06AA11, protriptyline, Protriptyline may decrease the hypoglycemic activities of Dapagliflozin.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Aripiprazole.]
[N07XX07, dalfampridine, Dapagliflozin may increase the excretion rate of Dalfampridine which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CC01, pyrantel, Dapagliflozin may increase the excretion rate of Pyrantel which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK01, pyrazinamide, Dapagliflozin may increase the excretion rate of Pyrazinamide which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AC01, pyrilamine, The metabolism of Dapagliflozin can be decreased when combined with Mepyramine.]
[C01BA01, quinidine, The metabolism of Dapagliflozin can be decreased when combined with Quinidine.]
[P01BC01, quinine, The metabolism of Dapagliflozin can be decreased when combined with Quinine.]
[D07AC10, diflorasone, The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Dapagliflozin.]
[A02BA02, ranitidine, Dapagliflozin may increase the excretion rate of Ranitidine which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AA01, rescinnamine, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Rescinnamine.]
[C02AA02, reserpine, Dapagliflozin may increase the excretion rate of Reserpine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AP01, ribavirin, Dapagliflozin may increase the excretion rate of Ribavirin which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AB02, rifampin, The metabolism of Dapagliflozin can be increased when combined with Rifampicin.]
[A07EC01, sulfasalazine, Sulfasalazine may increase the hypoglycemic activities of Dapagliflozin.]
[S01BC08, salicylic acid, Salicylic acid may increase the hypoglycemic activities of Dapagliflozin.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Dapagliflozin.]
[N04BD01, selegiline, Selegiline may increase the orthostatic hypotensive activities of Dapagliflozin.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Obinutuzumab.]
[A12CD01, sodium fluoride, Dapagliflozin may increase the excretion rate of Sodium fluoride which could result in a lower serum level and potentially a reduction in efficacy.]
[V04CC01, sorbitol, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Sorbitol.]
[C07AA07, sotalol, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Dapagliflozin.]
[C03DA01, spironolactone, The risk or severity of adverse effects can be increased when Spironolactone is combined with Dapagliflozin.]
[V09AB03, ioflupane I-123, Dapagliflozin may increase the excretion rate of Ioflupane I-123 which could result in a lower serum level and potentially a reduction in efficacy.]
[V09AA01, technetium Tc 99m exametazime, Dapagliflozin may increase the excretion rate of Technetium Tc-99m exametazime which could result in a lower serum level and potentially a reduction in efficacy.]
[N03AG01, valproic acid, The metabolism of Dapagliflozin can be decreased when combined with Valproic acid.]
[D07AB02, hydrocortisone butyrate, The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Dapagliflozin.]
